New at Retina Consultants

Valeda® light therapy for dry AMD.

The first and only FDA‑authorized treatment for dry age‑related macular degeneration. Gentle, multiwavelength light — no injections, no downtime — delivered in minutes, right in our offices.

Call to ask about Valeda See the research

The Valeda® Light Delivery System — clinician side (left) and patient side (right)

How it works

Light that recharges the retina.

Three precise wavelengths

Valeda delivers yellow (590 nm), red (660 nm) and near‑infrared (850 nm) light — each chosen to reach and support different layers of the retina.

Recharging the cells’ batteries

The light is absorbed by mitochondria — the tiny power plants inside retinal cells — boosting their energy production, improving oxygen use, and calming inflammation. In dry AMD, those cells are struggling for energy; Valeda addresses that directly.

Gentle by design

Eye‑safe LED light, delivered to the undilated eye while you sit comfortably. It is painless — at most a brief afterimage, like after a camera flash, fading within seconds.

The evidence

What the research showed.

In the pivotal U.S. LIGHTSITE III trial — 100 patients (148 eyes) at ten retina centers, randomized and double‑masked, with a sham (placebo‑style) treatment for comparison — Valeda met its primary goal: better vision than sham, sustained over two years of treatment.

+5.9 letters

Average vision gain from baseline at 24 months — more than a full line on the eye chart.

58%

of treated eyes gained five or more letters at 24 months; nearly one in five gained ten or more.

73% fewer

eyes developed new geographic atrophy — the advanced, vision‑destroying stage of dry AMD — over 24 months (6.8% vs 24% with sham).

First & only

FDA‑authorized treatment for dry AMD (De Novo authorization, November 2024).

Valeda vs. no treatment, side by side.

Three results from the same trial, shown simply. “Sham” means a placebo‑style session with only a trace of light — so neither patients nor doctors knew who received the real treatment.

Vision change at 13 months

Average change in letters read on the eye chart.

−2.3Untreated
eyes

+3.0Sham

+5.4Valeda

Eyes that lost vision

Share of eyes losing more than 5 letters over 24 months.

53% fewer with Valeda

18%Sham

7%Valeda

New geographic atrophy

Share of eyes progressing to GA, the advanced stage of dry AMD, over 24 months.

73% fewer with Valeda

24%Sham

6.8%Valeda

Figures from the peer‑reviewed LIGHTSITE III 13‑ and 24‑month analyses. The trial enrolled adults 50 and older with dry AMD and vision between roughly 20/32 and 20/70. Valeda is not a treatment for wet AMD, and individual results vary — your retina specialist will determine whether you are a candidate. Valeda® and the Valeda Light Delivery System are products of LumiThera, Inc.

Convenience

Built around your schedule.

≈4–5 min per eyeThat’s the entire light treatment — under ten minutes for both eyes.

≈15‑minute visitsMost appointments are done start‑to‑finish in about a quarter hour.

9 short visitsOne treatment series is nine sessions over three to five weeks.

A few series a yearSeries are typically repeated every four to six months to maintain the benefit.

Zero needlesNo injections, no dilation, no anesthesia — just remove your glasses and sit back.

No downtimeDrive yourself home and get right on with your day.

Wondering if Valeda is right for your eyes?

Ask about it at your next visit — or call and we’ll talk it through with you.

(410) 546‑8037